STEALTH BIOTHERAPEUTICS CORP (MITO)       0.32  0 (-1.36%)

0.32  0 (-1.36%)

US85789A1051 - ADR


Fundamental Rating

1

Overall MITO gets a fundamental rating of 1 out of 10. We evaluated MITO against 637 industry peers in the Biotechnology industry. Both the profitability and financial health of MITO have multiple concerns. MITO is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

0

MITO has negative profitability rations, so we won't be analyzing them here.
MITO has a Return On Assets of -143.50%. This is below the industry average of 12.41%. 100% of the industry peers outperform MITO.

The Piotroski-F score of MITO is 2.00. This is a very weak score and indicates problems in health and profitability for MITO.
VS Industry

ROA (-143.5%) VS Industry: 0% outperformed.

0.00
61.63

Valuation

Valuation Rating

0

MITO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MITO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

1

The earnings per share for MITO have decreased by 0.00% in the last year.

The Earnings Per Share is expected to grow by 4.98% on average over the next 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 0% 23.5% 16.73% 7.29% 4.98%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

2

MITO has a Current Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.68 indicates that MITO has no problem at all paying its short term obligations.
When comparing the Current Ratio of MITO to the average industry Current Ratio of 5.91, MITO is less able to pay its short term obligations than its industry peers.

Compared to an average industry Quick Ratio of 5.88, MITO is worse placed to pay its short term obligations than its industry peers.
MITO has a negative Debt to Equity ratio (-0.26), which implies it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
MITO has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for MITO.
VS Industry

Quick Ratio (3.68) VS Industry: 32% outperformed.

0.04
84.53

Current Ratio (3.68) VS Industry: 31% outperformed.

0.08
85.09

Dividend

Dividend Rating

0

No dividends for MITO!.

STEALTH BIOTHERAPEUTICS CORP0.32

NASDAQ:MITO (11/15/2022, 7:00:01 PM)0 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18 2022-11-18/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change-99.67%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.54M
Analysts82.86
Price Target1.81 (465.63%)
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.11%
Min EPS beat(2)50.98%
Max EPS beat(2)63.24%
EPS beat(4)3
Avg EPS beat(4)29.53%
Min EPS beat(4)-47.06%
Max EPS beat(4)63.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.07
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpS-0.71
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -143.5%
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc(3y)N/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z N/A
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50.28%
Cap/Depr(5y)39.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y0%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16%
OCF growth 3YN/A
OCF growth 5YN/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA